8-K Announcements
6Material company update
Dec 9, 2025·SEC
Material company update
Dec 3, 2025·SEC
Material company update
Oct 9, 2025·SEC
Akero Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is entirely contingent upon the successful development of its MASH therapeutic pipeline. While the company maintains a clean balance sheet with a debt-to-equity ratio of ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 7, 2025 | -$0.99-5.3% vs -$0.94 | — vs — |
Q3 2025 Aug 8, 2025 | -$0.86+11.3% vs -$0.97 | — vs — |
Q2 2025 May 12, 2025 | $0.90+189.1% vs -$1.01 | — vs — |
Q1 2025 Feb 28, 2025 | -$0.99-1.0% vs -$0.98 | — vs — |
Benchmark AKRO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Akero Therapeutics, Inc. (AKRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $54.65 | $4.5B | -14.57 | — | — | -39.22% | — | |
| $513.02 | $11.83B | -39.92 | 432.05% | -25.32% | -56.65% | — | |
| $112.44 | $13.34B | 43.92 | 37.55% | 24.86% | 180.63% | — | |
| $46.09 | $3.29B | -25.19 | — | — | -18.55% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $35.95 | $2.07B | -14.98 | — | — | -16.91% | — |
Akero Therapeutics, Inc. (AKRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Akero Therapeutics, Inc. (AKRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Dec 9, 2025·SEC
Dec 3, 2025·SEC
Oct 9, 2025·SEC
Feb 28, 2025·SEC
Get notified when AKRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Akero Therapeutics, Inc. (AKRO) stock FAQ — growth, dividends, profitability & financials explained
Akero Therapeutics, Inc. (AKRO) reported a net loss of $292.8M for fiscal year 2024.
Akero Therapeutics, Inc. (AKRO) has a return on equity (ROE) of -39.2%. Negative ROE indicates the company is unprofitable.
Akero Therapeutics, Inc. (AKRO) had negative free cash flow of $250.2M in fiscal year 2024, likely due to heavy capital investments.